all the information, none of the junk | biotech • healthcare • life sciences

C-Crete Wins $100K, BioSphere and Double-Take Get Taken Out, General Compression Adds to Series A, & More Boston-Area Deals News

Xconomy Boston — 

We saw a mix of headlines on early funding rounds, business plan competitions, and acquisitions from startups in the software, mobile hardware, Internet, energy, and biotech sectors.

—Cambridge, MA-based Sand 9, a maker of tiny timer and frequency control technology for wireless devices, said it secured a $12 million Series B financing, led by new investor Commonwealth Capital Ventures. The company, developing a resonator that could make devices such as GPS units, mobile phones, and wireless routers smaller and more integrated, previously raised an $8 million round that included backing from Flybridge Capital Partners, General Catalyst Partners, and Khosla Ventures.

—General Compression, a Newton, MA-based maker of compressor systems for storing wind energy, brought its Series A financing total to $20.9 million, with an additional $3 million from the Northwater Intellectual Property Fund. The earlier part of the Series A round included investments from Duke Energy and U.S. Renewables Group.

C-Crete nabbed $100,000 as the winner of MIT’s $100K Entrepreneurship Competition. The team, led by MIT civil engineering PhD candidate Rouzbeh Shahsavari, is developing a nanoengineered form of concrete that emits less carbon dioxide in the production process, and is cheaper and stronger than the traditional form of the building material. C-Crete lost earlier in the week in MIT’s Clean Energy Prize, where Stanford University team C3Nano took home $200,000 for its work in photovoltaic solar panels.

—-Cambridge-based LocaModa, which makes place-based social media software, raised $150,000 of a planned $1.5 million offering of equity, debts, and rights, an SEC filing revealed. The company had previously pulled in $900,000 in equity funding, according to a regulatory filing last June.

BioSphere Medical, a Rockland, MA-based developer of treatments for tumors, vascular malformations, and uterine fibroids, said it is being acquired by Utah-based Merit Medical Systems, for $96 million in cash. Merit (NASDAQ: MMSI) is paying $4.38 per share for BioSphere (NASDAQ: BSMD) common stock, a 54 percent premium over its closing price on May 12, the day before the agreement was announced. We profiled BioSphere back in October 2008.

—Stemgent, a company with offices in San Diego and Cambridge that makes consumable materials for stem cell research, pulled in $5.6 million of a planned $10.1 million equity round, which includes the conversion of some debt financing into equity stakes.

— Laparoscopic instrument maker Cambridge Endoscopic Devices wrapped up $3 million of a $7.5 million equity-based offering, from one investor, according to an SEC filing.

—Data protection and recovery software maker Double-Take Software, (NASDAQ: DBTK), announced it will be acquired by Vision Solutions in a deal with a net value of about $242 million. Vision, which is a portfolio company of private equity firm Thoma Bravo, will pay $10.55 per share for Southborough, MA-based Double-Take’s common stock, which represents a 21 percent premium over the $8.71 closing price the last business day before the company’s board expressed interest in an acquisition.

By posting a comment, you agree to our terms and conditions.

  • Cooper

    Is the same thing? Looks not a new idea…
    since 1996?


    Introduction to C*-Crete, A New Technology for Construction